AEON BiopharmaAEON
AEON
About: AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
Employees: 5
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more funds holding
Funds holding: 25 [Q2] → 30 (+5) [Q3]
15% more capital invested
Capital invested by funds: $8.73M [Q2] → $10.1M (+$1.32M) [Q3]
0.13% more ownership
Funds ownership: 24.09% [Q2] → 24.22% (+0.13%) [Q3]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
669%
upside
Avg. target
$5
669%
upside
High target
$5
669%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 72 / 168 met price target | 669%upside $5 | Buy Reiterated | 1 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –
Positive
Zacks Investment Research
4 months ago
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AEON Biopharma, Inc. (AEON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
4 months ago
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON's President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
Neutral
GlobeNewsWire
4 months ago
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –
Positive
Zacks Investment Research
6 months ago
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
6 months ago
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline
Neutral
GlobeNewsWire
7 months ago
AEON Biopharma Reports First Quarter 2024 Financial Results
– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints –
Negative
Zacks Investment Research
7 months ago
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AEON Biopharma, Inc. (AEON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
7 months ago
AEON Biopharma Provides Update on Development Pipeline
Includes two late-stage clinical programs and two early-stage clinical programs Includes two late-stage clinical programs and two early-stage clinical programs
Neutral
GlobeNewsWire
7 months ago
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint.
Charts implemented using Lightweight Charts™